Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

ROCHESTER, New York, August 26 /PRNewswire/ --

- Aggressive Three Week Deployment Schedule Brings Advanced, International Signalling Capabilities to Fiji

Performance Technologies (Nasdaq: PTIX), a leading developer of communication platforms and systems, today announced that Fiji International Telecommunications Limited (FINTEL) has implemented the company's SEGway(TM) STP Signalling Solution with Point Code Emulation(TM) (PCE) technology to meet its high-growth, international signalling requirements. FINTEL, partially owned by Cable & Wireless, provides international telecommunications service to and through the South Pacific Island of Fiji.

ROCKVILLE, Maryland, August 26 /PRNewswire/ --

- VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness

Novavax, Inc. (Nasdaq: NVAX) announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain. Avian influenza emerged in humans in Indonesia in 2005 and has caused 135 documented human cases, 81% of which have been fatal. (1)

LAVAL, Canada, August 26 /PRNewswire/ -- The Laval-based firm Algorithme Pharma is pleased to announce that it has achieved its goal of securing a European facility through its acquisition of Simbec Research Ltd in Merthyr Tydfil, Wales. This news comes only six weeks after confirming the purchase of another clinical research centre in Baltimore, Maryland.

This important acquisition will enable Algorithme Pharma, a worldwide leader in clinical research and bioanalysis, to continue its international expansion plans, establish a foothold in Europe for the very first time in its history and, most importantly, obtain additional advanced scientific and medical expertise for its North American teams.

LONDON, August 26 /PRNewswire/ --

- Exhibition Designer Calls for Photos of British Public

- With Photo

People across the UK are being given a once-in-a-lifetime opportunity to be a part of BODY WORLDS, the groundbreaking anatomical exhibition by trailblazing scientist Gunther von Hagens, opening at The O2 on October 24th.

SAN JOSE, California, August 26 /PRNewswire/ --

- The United States Patent Office Has Granted Finjan a New Patent That Provides Businesses With Features for Scanning and Caching Content at the Gateway

Finjan Inc., a leading provider of secure web gateway solutions for the enterprise market, today announced that the United States Patent Office has granted the company Patent No. 7,418,731 for "Method and system for caching at secure gateways". This patent further adds to Finjan's extensive and comprehensive intellectual property portfolio in the security market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080618/309345 )

YOQNEAM, Israel and SAN RAMON, California, August 26 /PRNewswire/ -- UltraShape, the global leader in non-invasive fat reduction and body contouring, announced today the appointment of Assaf Eyal as President and Chief Executive Officer.

Assaf most recently served as Executive Vice President at NUR Macroprinters, a manufacturer of super-wide format digital printers and inks, While at NUR, Assaf was a member of a small leadership team that led to a successful sale to HP. Previously, he served in various positions at Orbotech Ltd., (NASDAQ: ORBK) over a seventeen year period, most recently as Co-President of the Display Division and Corporate VP, a division that grew under his leadership to revenues of $150 million. He holds a B.Sc in Engineering and M.Sc in Management.